Sugi Predict

Sugi Predict / Compounds / SCHEMBL2202801

SCHEMBL2202801

SCHEMBL2202801

C[C@H]1C[C@H](O)CN1C(=O)OC(C)(C)C

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CHRM2 P08172 1/20 0.49
▸ CHRM1 P11229 1/20 0.49
▸ CHRM3 P20309 1/20 0.49
▸ CYP1A2 P05177 1/20 0.45
▸ POLB P06746 1/20 0.45
▸ CYP3A4 P08684 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ NR1H2 P55055 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ ATM Q13315 1/20 0.37
▸ HSD11B1 P28845 1/20 0.36
▸ USP2 O75604 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ DPP4 P27487 2/20 0.36
▸ DPP8 Q6V1X1 2/20 0.36
▸ DPP9 Q86TI2 2/20 0.36
▸ HSD17B10 Q99714 1/20 0.35
▸ GPR119 Q8TDV5 1/20 0.35
▸ PIK3CD O00329 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3247661 1.00 CHRM2 (0.49) CHRM2CHRM1CHRM3CYP1A2POLB
SCHEMBL764147 1.00 CHRM2 (0.49) CHRM2CHRM1CHRM3CYP1A2POLB
SCHEMBL2202251 1.00 CHRM2 (0.49) CHRM2CHRM1CHRM3CYP1A2POLB
SCHEMBL764122 1.00 CHRM2 (0.49) CHRM2CHRM1CHRM3CYP1A2POLB
SCHEMBL13079208 1.00 CHRM2 (0.49) CHRM2CHRM1CHRM3CYP1A2POLB
SCHEMBL4881170 1.00 CHRM2 (0.49) CHRM2CHRM1CHRM3CYP1A2POLB
SCHEMBL376321 1.00 CHRM2 (0.49) CHRM2CHRM1CHRM3CYP1A2POLB
Pyrazine SCHEMBL31128788 0.91 CYP1A2 (0.43) CHRM2CHRM1CHRM3CYP1A2POLB
SCHEMBL23564630 0.86 CHRM2 (0.45) CHRM2CHRM1CHRM3CYP1A2POLB
SCHEMBL16853219 0.86 CHRM2 (0.45) CHRM2CHRM1CHRM3CYP1A2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12522595-B2 Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors BIOGEN MA INC. (US) 2026-01-13 — — US disclosed
US-12492208-B2 Crystal of pyrimidine compound TAIHO PHARMACEUTICAL CO., LTD. (JP) 2025-12-09 — — US disclosed
EP-4642773-A1 NEW BENZIMIDAZOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2025-11-05 — — EP disclosed
US-12447153-B2 HER2 mutation inhibitors PFIZER INC. (US) 2025-10-21 — — US disclosed
EP-4301468-B1 FGFR3 INHIBITOR COMPOUNDS LILLY CO ELI (US) 2025-09-03 — — EP disclosed
EP-3590516-B1 ANTITUMOR-EFFECT ENHANCER USING PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND TAIHO PHARMACEUTICAL CO LTD (JP) 2025-09-03 — — EP disclosed
EP-4547658-A1 WEE1 DEGRADING COMPOUNDS AND USES THEREOF Bristol-Myers Squibb Company (US) 2025-05-07 — — EP disclosed
US-20250122196-A1 FGFR3 INHIBITOR COMPOUNDS ELI LILLY AND COMPANY 2025-04-17 — — US disclosed
US-12275728-B2 O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors BIOGEN MA INC. (US) 2025-04-15 — — US disclosed
CN-116249534-B Crystallization of pyrimidine compounds 大鹏药品工业株式会社 2025-03-25 — — CN disclosed
US-7834021-B2 3-aminopyrrolidine derivatives as modulators of chemokine receptors INCYTE CORPORATION (US) 2010-11-16 — — US disclosed
EP-2182953-A2 NEW PYRAZOL DERIVATIVES F. Hoffmann-Roche AG (CH) 2010-05-12 — — EP disclosed
US-20090264431-A1 NOVEL CATHEPSIN C INHIBITORS AND THEIR USE GLAXO GROUP LIMITED (GB) 2009-10-22 — — US disclosed
US-20090264431-A1 NOVEL CATHEPSIN C INHIBITORS AND THEIR USE GLAXO GROUP LIMITED (GB) 2009-10-22 — — US disclosed
US-20090247474-A1 3-Aminopyrrolidine Derivatives As Modulators Of Chemokine Receptors INCYTE CORPORATION 2009-10-01 — — US disclosed
WO-2009026197-A1 NOVEL CATHEPSIN C INHIBITORS AND THEIR USE GLAXO GROUP LIMITED (GB) 2009-02-26 — — WO disclosed
WO-2009026197-A1 NOVEL CATHEPSIN C INHIBITORS AND THEIR USE GLAXO GROUP LIMITED (GB) 2009-02-26 — — WO disclosed
US-20090029963-A1 PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 — — US disclosed
WO-2009013211-A2 NEW PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 — — WO disclosed
US-20070117986-A1 TRANS-3,5-DISUBSTITUTEDPYRROLIDINE: ORGANOCATALYST FOR anti-MANNICH REACTIONS THE SCRIPPS RESEARCH INSTITUTE 2007-05-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264431-A1 NOVEL CATHEPSIN C INHIBITORS AND THEIR USE CTSB, CTSS, CTSF CHRM2 180/4885CHRM1 233/4885CHRM3 450/4885
US-12492208-B2 Crystal of pyrimidine compound DPYD, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NT5C3B CHRM2 4412/4885CHRM1 4296/4885CHRM3 4682/4885
US-20090247474-A1 3-Aminopyrrolidine Derivatives As Modulators Of Chemokine Receptors CCR2, CXCR3, CCR5 CHRM2 69/4885CHRM1 63/4885CHRM3 161/4885
US-20070117986-A1 TRANS-3,5-DISUBSTITUTEDPYRROLIDINE: ORGANOCATALYST FOR anti-MANNICH REACTIONS HRH4, NR1I3, NR1I2 CHRM2 125/4885CHRM1 30/4885CHRM3 132/4885
US-20090029963-A1 PYRAZOL DERIVATIVES CCR1, CCR3, CCRL2 CHRM2 266/4885CHRM1 308/4885CHRM3 75/4885
US-20250122196-A1 FGFR3 INHIBITOR COMPOUNDS FGFR3, FGFR1, FGFR2 CHRM2 4498/4885CHRM1 4157/4885CHRM3 4387/4885
US-12447153-B2 HER2 mutation inhibitors ERBB2, EGFR, ERBB3 CHRM2 2009/4885CHRM1 1931/4885CHRM3 3801/4885
US-12275728-B2 O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors MGAT3, MAN2A1, ENGASE CHRM2 1025/4885CHRM1 1292/4885CHRM3 1649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.